Jon P. Stonehouse, President, Chief Executive Officer of BioCryst

BioCryst bags $250M in a debt and roy­al­ty deal as the ex­ec­u­tive team preps a new drug launch for HAE

Three days af­ter land­ing an FDA OK for their HAE drug bero­tral­stat, BioCryst $BCRX now has some cash to see how far they can go in com­mer­cial­iz­ing the ther­a­py as Or­ladeyo.

The biotech re­port­ed Mon­day morn­ing that they’ve inked a deal with Roy­al­ty Phar­ma that trades a chunk of their rev­enue from the drug for cash in hand. Roy­al­ty is pay­ing out $125 mil­lion up­front, with a $200 mil­lion cred­it fa­cil­i­ty from Athyri­um Cap­i­tal Man­age­ment that is be­ing tapped for $125 mil­lion right off the bat. The rest will be held in re­serve.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.